NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $16.00 +0.14 (+0.88%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$15.68 -0.32 (-2.03%) As of 08/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Korro Bio alerts:Sign Up Key Stats Today's Range$15.69▼$16.8950-Day Range$10.80▼$16.8552-Week Range$10.29▼$98.00Volume87,100 shsAverage Volume121,590 shsMarket Capitalization$150.26 millionP/E RatioN/ADividend YieldN/APrice Target$102.43Consensus RatingBuy Company Overview Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 28% of companies evaluated by MarketBeat, and ranked 800th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 3 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.04% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Korro Bio has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.04% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Korro Bio has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Korro Bio this week, compared to 3 articles on an average week.Search Interest1 people have searched for KRRO on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Korro Bio is held by insiders.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRRO Stock News HeadlinesKorro Receives European Medicines Agency Orphan Drug Designation for KRRO-110July 21, 2025 | globenewswire.comKorro Bio, Inc. (KRRO) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 10 at 2:00 AM | Brownstone Research (Ad)Korro to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)May 14, 2025 | theglobeandmail.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $38.07 at the start of the year. Since then, KRRO stock has decreased by 58.0% and is now trading at $16.00. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) posted its earnings results on Wednesday, May, 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $0.11. The business had revenue of $2.55 million for the quarter, compared to analysts' expectations of $0.13 million. Who are Korro Bio's major shareholders? Top institutional investors of Korro Bio include Geode Capital Management LLC (1.65%) and AlphaQuest LLC (0.29%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/07/2025Today8/10/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Korro Bio$102.43 High Price Target$180.00 Low Price Target$25.00 Potential Upside/Downside+540.2%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($9.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.58 million Net MarginsN/A Pretax Margin-1,810.56% Return on Equity-51.64% Return on Assets-37.94% Debt Debt-to-Equity RatioN/A Current Ratio9.41 Quick Ratio9.41 Sales & Book Value Annual Sales$4.82 million Price / Sales31.17 Cash FlowN/A Price / Cash FlowN/A Book Value$17.12 per share Price / Book0.93Miscellaneous Outstanding Shares9,391,000Free Float8,959,000Market Cap$150.26 million OptionableNo Data Beta2.51 Social Links 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:KRRO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.